文献速递主动脉疾病

Zenith t-Branch 胸腹主动脉腔内移植物的上市后早期与中期结果

Early and midterm results from a postmarket observational study of Zenith t-Branch thoracoabdominal endovascular graft.
PubMed 文献 · J Vasc Surg · 2021-03-05

本研究为上市后多中心观察性研究,纳入2012年9月至2017年11月三家欧洲中心使用Zenith t-Branch多分支胸腹主动脉支架治疗的80例患者,评估30天和1年手术相关死亡率、并发症及内漏、装置完整性和分支血管通畅性。结果显示装置置入成功79例,30天死亡率1.3%,1年死亡率8.8%,无主动脉破裂或中转开放手术,结论认为该装置安全。

要点

  • 30天死亡1例(1.3%),1年死亡7例(8.8%),无主动脉破裂或中转开放手术。
  • 30天卒中3例(3.8%),截瘫1例(1.3%),不全瘫6例(7.5%)。
  • 随访期间9例(11.3%)需二次干预;1年时主支架通畅率100%。

核心结论

  • Zenith t-Branch装置在稳定和有症状病例中均显示出良好的30天和1年死亡率和并发症率,初步认为安全。

研究设计与样本

  • 上市后多中心观察性研究,纳入2012年9月至2017年11月三家欧洲中心使用t-Branch装置治疗的80例患者,平均年龄71.0±7.4岁,男性占70.0%。
  • 77例为胸腹主动脉瘤(TAAA),3例为夹层;TAAA中稳定型占72.7%(56/77),有症状占7.8%(6/77),局限性破裂占19.5%(15/77)。

主要发现

  • 装置成功置入79例,1例因输送系统无法通过髂动脉而未置入。
  • 30天内死亡1例(1.3%);1年死亡7例(8.8%),无主动脉破裂或中转开放手术。
  • 30天神经系统事件包括卒中3例(3.8%)、截瘫1例(1.3%)、不全瘫6例(7.5%)。
  • 随访期间9例(11.3%)接受二次干预。
  • 术后内漏见于37/72例(51.4%),其中II型30例、Ia型4例、III型6例;1年时20例报告内漏(II型16例、III型4例)。

临床怎么用

  • 对于不适合开放手术的胸腹主动脉瘤患者,t-Branch作为一种即用型多分支支架可考虑使用,但需注意术后内漏和神经系统并发症风险。

局限性

  • 样本量较小(80例),部分患者为回顾性纳入,随访时间仅1年,远期耐久性有待进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We have reported the short-term outcomes regarding the safety of the off-the-shelf Zenith t-Branch multibranched thoracoabdominal stent-graft (William Cook Europe ApS, Bjaeverskov, Denmark) in a postmarket, multicenter study. METHODS: Patients who had been treated with the t-Branch device from September 2012 to November 2017 at three European centers were either prospectively or retrospectively enrolled in the present study. Device implantation and postprocedural follow-up were performed according to the standard of care at each center. The primary objectives of the present study were to assess the procedure-related mortality and morbidity at 30 days and 1 year and to assess the presence of endoleaks, device integrity, and stent-graft and branch vessel patency. RESULTS: A total of 80 patients were included in the present study (mean age, 71.0 ± 7.4 years; 70.0% male). Most (n = 77) had been treated for thoracoabdominal aortic aneurysms (TAAAs) and the rest for dissection (n = 3). Most TAAAs were stable (72.7%; 56 of 77). The remaining TAAAs were symptomatic (7.8%; 6 of 77) or had a contained rupture (19.5%; 15 of 77). The t-Branch device was successfully deployed in 79 patients. In one patient, the delivery system of the device could not be advanced through the iliac artery. Within 30 days, one patient had died (1.3%). At 1 year, seven patients had died (8.8%), and no aortic rupture or conversion to open surgery had been reported. The 30-day neurologic events included stroke in three patients (3.8%), paraplegia in one (1.3%), and paraparesis in six patients (7.5%). Secondary interventions were required in nine patients (11.3%) during follow-up. Postoperative endoleaks were observed in 37 of 72 patients (51.4%), including type II endoleak in 30, type Ia in 4, and type III endoleak in 6 patients. At 1 year, endoleaks had been reported in 20 patients (16 with type II and 4 with type III). The t-Branch main body graft patency was 100% throughout the 1-year follow-up period. At 30 days after the procedure, all celiac and superior mesenteric artery branches were patent and one left renal and one right renal branch were occluded. At 1 year, occlusion had developed in three bridging stent-grafts for the celiac artery, one for the left renal artery, and two for the right renal artery. CONCLUSIONS: The t-Branch device appears safe, with good 30-day and 1-year mortality and morbidity in the present study, including both stable and symptomatic cases.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Bosiers M, Kölbel T, Resch T, et al. Early and midterm results from a postmarket observational study of Zenith t-Branch thoracoabdominal endovascular graft. J Vasc Surg. 2021. PMID: 33684474. doi:10.1016/j.jvs.2021.01.070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。